Bringing a new drug to market is not without risk. Certainly every pharmaceutical has completed rigorous analysis and determined acceptable risk tolerances for everything, from adverse events to re-submission delays. Even still, it is nerve racking making the decision to initiate new drug development research given the lengthy timelines and costs associated with a drug. […]
There are tremendous risks associated when developing a new drug. Ordinarily a drug lifecycle is between 10-12 years and teams are bound to encounter unforeseen hurdles. If teams are not utilizing the same processes and tracking their progress in the same way that can result in unforeseen delays and loss of data. It is critical […]
“Why do I have to keep updating the stakeholders? I just sent them a progress report a few days ago and nothing has changed…,” a question project managers ask themselves all too often. Obviously, the stakeholders have invested a significant portion of money into the development of the new drug and he/she is always in […]
The next big market share grab will go to the organization that figures out how to reduce the number of resubmissions to the Food and Drug Administration (FDA) , and thus reduce the time it takes to get a product to market. When you have a project on a large scale such as the development […]
Last week Aurotech attended the HIMSS 2016 conference in Las Vegas. Our purpose was to raise awareness for our company within the Health IT space. More than 50,000 people were in attendance. Including health IT professionals, clinicians, executives and vendors from around the world. An overwhelming number of people visited our booth. We featured both […]
There have been volumes said about the benefits and woes of centralized decision-making. An equal amount has been written touting the benefits and woes of decentralized decision-making. I think it is safe to say that in different situations one decision-making approach is better than another. I would also maintain that there is space for both […]